CR20220366A - Método para el tratamiento del síndrome de usher y composición del mismo - Google Patents
Método para el tratamiento del síndrome de usher y composición del mismoInfo
- Publication number
- CR20220366A CR20220366A CR20220366A CR20220366A CR20220366A CR 20220366 A CR20220366 A CR 20220366A CR 20220366 A CR20220366 A CR 20220366A CR 20220366 A CR20220366 A CR 20220366A CR 20220366 A CR20220366 A CR 20220366A
- Authority
- CR
- Costa Rica
- Prior art keywords
- rna
- arrna
- target
- target rna
- usher syndrome
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Se provee un método para la edición dirigida de ARN diana que contiene una mutación G a A en un transcrito de gen USH2A con base en tecnología LEAPER, que comprende: introducir un constructo de un ARN de reclutamiento de adenosina desaminasa (arARN) para editar el ARN diana o un constructo que codifica dicho arARN en una célula, en donde el arARN comprende una secuencia de ARN complementaria que se hibrida al ARN diana, y en donde el arARN es capaz de reclutar adenosina desaminasa que actúa en el ARN (ADAR), de modo que la adenosina diana en el ARN diana es desaminada, realizando de este modo la edición in vivo de la base de A a I en el ARN de manera segura y eficaz, reparando un sitio de mutación patogénica, y logrando el propósito de tratar una enfermedad tal como el síndrome de Usher.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019129957 | 2019-12-30 | ||
PCT/CN2020/141501 WO2021136404A1 (zh) | 2019-12-30 | 2020-12-30 | 一种治疗Usher综合征的方法和其组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20220366A true CR20220366A (es) | 2022-11-28 |
Family
ID=76687119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20220366A CR20220366A (es) | 2019-12-30 | 2020-12-30 | Método para el tratamiento del síndrome de usher y composición del mismo |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230067480A1 (es) |
EP (1) | EP4086346A4 (es) |
JP (1) | JP2023509177A (es) |
KR (1) | KR20220118512A (es) |
CN (1) | CN114829598A (es) |
AU (1) | AU2020418026A1 (es) |
BR (1) | BR112022012921A2 (es) |
CA (1) | CA3163280A1 (es) |
CO (1) | CO2022010430A2 (es) |
CR (1) | CR20220366A (es) |
EC (1) | ECSP22059858A (es) |
IL (1) | IL294260A (es) |
MX (1) | MX2022008197A (es) |
TW (1) | TW202138561A (es) |
WO (1) | WO2021136404A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017281497B2 (en) | 2016-06-22 | 2023-04-06 | Proqr Therapeutics Ii B.V. | Single-stranded RNA-editing oligonucleotides |
SG11202111401RA (en) | 2019-04-15 | 2021-11-29 | Edigene Inc | Methods and compositions for editing rnas |
WO2021008447A1 (en) | 2019-07-12 | 2021-01-21 | Peking University | Targeted rna editing by leveraging endogenous adar using engineered rnas |
JP2023504314A (ja) | 2019-12-02 | 2023-02-02 | シェイプ セラピューティクス インコーポレイテッド | 治療的編集 |
WO2023152371A1 (en) | 2022-02-14 | 2023-08-17 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
WO2024013361A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
WO2024013360A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
WO2024110565A1 (en) | 2022-11-24 | 2024-05-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
WO2024121373A1 (en) | 2022-12-09 | 2024-06-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD128000A1 (de) | 1976-10-19 | 1977-10-26 | Gerhard Wuerker | Steuereinrichtung fuer einen zwei hauptpumpen besitzenden hydraulischen antrieb |
WO2015134812A1 (en) * | 2014-03-05 | 2015-09-11 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa |
US10617707B2 (en) * | 2016-04-25 | 2020-04-14 | Proqr Therapeutics Ii B.V. | Oligonucleotides to treat eye disease |
GB201616202D0 (en) * | 2016-09-23 | 2016-11-09 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of eye deisease |
EP3728594A1 (en) * | 2017-12-21 | 2020-10-28 | CRISPR Therapeutics AG | Materials and methods for treatment of usher syndrome type 2a |
BR112020019079A2 (pt) * | 2018-03-23 | 2020-12-29 | Massachusetts Eye And Ear Infirmary | Abordagem de salto de éxon mediada por crispr/cas9 para síndrome de usher associada a ush2a |
CA3115864A1 (en) | 2018-10-12 | 2020-04-16 | Peking University | Methods and compositions for editing rnas |
SG11202111401RA (en) * | 2019-04-15 | 2021-11-29 | Edigene Inc | Methods and compositions for editing rnas |
-
2020
- 2020-12-30 TW TW109146911A patent/TW202138561A/zh unknown
- 2020-12-30 WO PCT/CN2020/141501 patent/WO2021136404A1/zh unknown
- 2020-12-30 BR BR112022012921A patent/BR112022012921A2/pt not_active Application Discontinuation
- 2020-12-30 CR CR20220366A patent/CR20220366A/es unknown
- 2020-12-30 JP JP2022540983A patent/JP2023509177A/ja active Pending
- 2020-12-30 EP EP20909536.3A patent/EP4086346A4/en active Pending
- 2020-12-30 US US17/790,484 patent/US20230067480A1/en active Pending
- 2020-12-30 KR KR1020227024955A patent/KR20220118512A/ko not_active Application Discontinuation
- 2020-12-30 AU AU2020418026A patent/AU2020418026A1/en active Pending
- 2020-12-30 IL IL294260A patent/IL294260A/en unknown
- 2020-12-30 CN CN202080086703.4A patent/CN114829598A/zh active Pending
- 2020-12-30 MX MX2022008197A patent/MX2022008197A/es unknown
- 2020-12-30 CA CA3163280A patent/CA3163280A1/en active Pending
-
2022
- 2022-07-26 CO CONC2022/0010430A patent/CO2022010430A2/es unknown
- 2022-07-29 EC ECSENADI202259858A patent/ECSP22059858A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023509177A (ja) | 2023-03-07 |
CO2022010430A2 (es) | 2022-08-09 |
US20230067480A1 (en) | 2023-03-02 |
EP4086346A1 (en) | 2022-11-09 |
MX2022008197A (es) | 2022-08-02 |
KR20220118512A (ko) | 2022-08-25 |
IL294260A (en) | 2022-08-01 |
BR112022012921A2 (pt) | 2022-09-06 |
CA3163280A1 (en) | 2021-07-08 |
ECSP22059858A (es) | 2022-11-30 |
AU2020418026A1 (en) | 2022-08-18 |
WO2021136404A1 (zh) | 2021-07-08 |
TW202138561A (zh) | 2021-10-16 |
EP4086346A4 (en) | 2024-03-20 |
CN114829598A (zh) | 2022-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022008197A (es) | Metodo para el tratamiento del sindrome de usher y composicion del mismo. | |
US20240002835A1 (en) | Genetic tool for the transformation of clostridium bacteria | |
MX2022008190A (es) | Metodo basado en tecnologia leaper para el tratamiento de mucopolisacaridosis ih y composicion. | |
WO2020183414A3 (en) | Modifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells | |
NO874673D0 (no) | Genetisk manipulerte planteceller og planter som utviser resistens overfor glutaminsyntetase-inhibitorer, dna-fragmenter og rekombinanter for bruk ved fremstilling av nevnte celler og planter. | |
JP2002535995A5 (es) | ||
MX2022012985A (es) | Metodo y farmaco para tratar el sindrome de hurler. | |
IL292512B1 (en) | CRISPR-CAS-related methods, compositions and components for cancer immunotherapy | |
Kohchi et al. | Structure and organization of Marchantia olymorpha chloroplast genome: IV. Inverted repeat and small single copy regions | |
Yan et al. | The complete mitochondrial genome sequence of the western flower thrips Frankliniella occidentalis (Thysanoptera: Thripidae) contains triplicate putative control regions | |
CN103820452B (zh) | 一种sgRNA片段及其应用 | |
JP2019500036A (ja) | 原核生物におけるdna末端修復経路の再構築 | |
Ublinskaya et al. | A PCR-free cloning method for the targeted φ80 Int-mediated integration of any long DNA fragment, bracketed with meganuclease recognition sites, into the Escherichia coli chromosome | |
Karagyaur et al. | Practical recommendations for improving efficiency and accuracy of the CRISPR/Cas9 genome editing system | |
AR124149A1 (es) | Método para producir plantas de papa con pardeamiento suprimido mediante el sistema crispr / cas9 | |
WO2020165901A8 (en) | Site specific recombinase integrase variants and uses thereof in gene editing in eukaryotic cells | |
WO2023201270A3 (en) | Therapeutic applications of crispr type v systems | |
Banerjee et al. | Non-random DNA damage resulting from heat treatment: implications for sequence analysis of ancient DNA | |
WO2023015205A3 (en) | Compositions and methods for improved gene editing | |
NAKAMICHI et al. | Somatic tissues of the coral Galaxea fascicularis possess telomerase activity | |
CN104560972A (zh) | 一种pcr引物及其修饰方法及基于平行高通量单分子高保真扩增方法 | |
Haque et al. | Optimizing the utilization of chemically modified Cas9 mRNA/sgRNA against the underlying genetic defect in Surfactant Protein B deficiency and Cystic fibrosis based on expression kinetics. | |
US20240132873A1 (en) | Site-specific genome modification technology | |
US20240229012A9 (en) | Site-specific genome modification technology | |
MX2023000035A (es) | Método de tratamiento de edición del gen de la deficiencia de piruvato quinasa (pkd). |